Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”

Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”

Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”

Hariri, Celularity’s CEO, Chairman and Founder, will open the meeting with the keynote address highlighting recent progress and important next steps for the science of longevity together with Scott Gottlieb, M.D., Senior Fellow of the American Enterprise Institute and former Commissioner of the U.S. Food and Drug Administration

FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that Robert Hariri, M.D., Ph.D., Celularity’s Chief Executive Officer, Chairman and Founder, will kick off the International Precision Medicine Center (IPMC) Conference, April 11-12th, in Goyang City, Republic of Korea, delivering the keynote address together with Scott Gottlieb, M.D., Senior Fellow of the American Enterprise Institute and former Commissioner of the U.S. Food and Drug Administration.

This year’s conference theme is, “Beyond Longevity: Live 120 Like 50,” and thought leaders from around the world are expected to participate. Dr. Hariri will drive interactive discussions about the latest advances in cell and gene therapy that contribute to enhanced longevity, how these advances are creating new options in medicine, and new opportunities once thought to be out of reach for people as they age.

“Our understanding of longevity, and the age-related biological processes like frailty that underlie aging, continues to grow at a rapid pace,” said Dr. Hariri. “Many of these processes take place at the cellular level, and cell therapy may well offer benefits that extend longevity and performance. The scientific community needs to conduct well-controlled studies to examine this hypothesis thoroughly.”

The conference will conclude with a working session on building a global longevity science hub in Goyang City, Republic of Korea, that is focused on advancing longevity science as its primary mission.

About the International Precision Medicine Center

Located in Goyang City, Republic of Korea, IPMC is devoted to building a global ecosystem and standard service platform of precision medicine and personalized medicine industry. Its mission is to:

  • Build the world’s first precision medicine center focused on cell therapy;
  • Take a pioneering role in standardization of future medicine;
  • Become a base for a service-centric precision medicine business focused on genome and bio-convergence technology;
  • Organize the world’s largest personalized medicine and preventative medicine conference; and
  • Serve as a global innovative technology and knowledge hub.

IPMC will be a global bio-service complex to realize the world’s first bio-ecosystem and the starting point of the global smart city. Envisioned to be the world’s first precision medical service and community complex focused on cell therapy, IPMC will contribute to scientific development and discovery of effective treatments for human diseases and will play a pioneering role in future standardization of future medicine.

About Celularity

Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company leading the next evolution in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. These therapeutic programs target indications in autoimmune, infectious and degenerative diseases, and cancer. In addition, Celularity develops, manufactures, and commercializes innovative biomaterial products also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

To learn more, visit celularity.com

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include express or implied statements regarding Celularity’s ability to advance its technology platform to develop therapeutic options for patients, among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: the inherent risks in biotechnological development, including with respect to the development of novel biomaterial products and cellular therapies, and the clinical trial and regulatory approval process; and risks associated with Celularity’s current liquidity, as well as developments relating to Celularity’s competitors and industry, along with those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2023, and other filings with the SEC. These risks and uncertainties may be amplified by current economic situations, including inflation, supply chain issues and overall economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Celularity Contact:
Paul Graves, Chief Communications Officer
Celularity Inc.